Biomea Fusion Inc., a clinical-stage company focused on diabetes and obesity medicines, announced that it will present new preclinical data at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. The presentations will highlight preclinical efficacy results for BMF-650, an oral small molecule GLP-1 receptor agonist, as well as combination data for icovamenib, a covalent menin inhibitor, with semaglutide, a GLP-1 based therapy. All abstracts are set to be published in a supplement of the Obesity journal. The results will be presented at the conference and have not yet been disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565128-en) on October 30, 2025, and is solely responsible for the information contained therein.